Axogen, Inc. (NASDAQ:AXGN) has seen insider movement following a period of intense stock price appreciation. According to filings submitted to the SEC, Chief Financial Officer Lindsey Marie Hartley reported transactions involving the company's common stock on May 7, 2026. During these transactions, Ms. Hartley sold a total of 1,051 shares of Axogen common stock for a total value of approximately $45,897. The shares were liquidated at a price point of $43.67 per share.
This selling activity takes place against the backdrop of a substantial upward trend for AXGN, which has experienced a 245% surge over the past year. At the time of these transactions, the stock was trading in the vicinity of its 52-week high, which stands at $45.83. The sale follows a series of acquisitions by Ms. Hartley through the exercise of employee stock options. Prior to the sale, she acquired 5,463 shares of common stock at prices ranging from $8.20 to $8.27 per share, an investment totaling roughly $45,004.
The details of these option exercises are as follows:
- Ms. Hartley exercised options for 2,500 shares of common stock at a price of $8.20 per share; these options reached full vesting on March 16, 2026.
- Additionally, she exercised options for 2,963 shares at a price of $8.27 per share. These specific shares are subject to a vesting schedule and are expected to be fully vested by March 16, 2027.
Following the execution of these trades, Lindsey Marie Hartley maintains a direct holding of 65,146 shares of Axogen, Inc. common stock. While the company's recent performance has been robust, some analytical assessments suggest the stock may currently be overvalued based on Fair Value metrics.
The insider transactions coincide with a period of notable financial momentum for the company. Axogen recently released its first-quarter 2026 earnings report, which highlighted significant top-line success. The company reported revenue of $61.5 million, representing a 27% increase year-over-year. This figure outperformed several analyst projections.
Market analysts have responded to these results by adjusting their outlooks:
- H.C. Wainwright raised its price target for Axogen to $50 while maintaining a Buy rating, noting that the $61.5 million revenue surpassed their expected $59 million.
- Mizuho increased its price target to $55, pointing toward strong top-line growth that exceeded the Street's estimate of 18%.
- Citizens also moved its price target up to $50, citing record sales and a level of growth not observed in more than four years.
Despite the revenue success, the company did report a slight miss on earnings per share (EPS), which came in at $0.07 against a forecasted $0.08. Additionally, Axogen reported a net loss of $19.6 million, a figure that was influenced by a $16.8 million loss related to the extinguishment of debt. Nonetheless, the company's revenue trajectory has contributed to a generally positive reception among investors and analysts.